

### **REMARKS**

Applicants' representative, Jing G. Sun, thanks Examiner Aulakh for the helpful and courteous telephone discussion of January 27, 2006.

#### **Status**

Upon entry of the amendments, Claims 1-2, 5-21, and 37-50 will be pending in this application. Support for the amendments can be found in the original claims and throughout the specification (pages 54 and 2). No new matter will have been added upon entry of the amendments.

The indication of allowed subject matter is acknowledged with appreciation.

#### **Response to Rejections under 35 U.S.C. §112, 1<sup>st</sup> ¶**

Claims 19-21 were rejected under the first paragraph of 35 U.S.C. §112. Applicants have amended the claims as suggested by the Examiner. In addition to the disclosure in the original specification, Applicants respectfully direct Examiner's attention to the arguments presented in the response of November 23, 2005 and the references attached therewith. Given the disclosure in the application and the state of the art of medicine, Applicants respectfully submit that the amended claims 19-21 have obviated the rejections under § 112, first paragraph. It is respectfully requested that these rejections be withdrawn.

Claims 47-51 were rejected under the first paragraph of 35 U.S.C. §112. Claim 51 has been canceled without prejudice or disclaimer. During the discussion of January 27, 2006, it was agreed that support for isoquinoline ring substituted with -N(PG)s in formula of claim 47 can be found in the disclosure on pages 43 and 46-47; and no new matter had been introduced by claims 47-50. Hence, it is respectfully requested that these rejections be withdrawn.


**Response to Rejection Under 35 U.S.C. §112, 2<sup>nd</sup> ¶**

Claims 19 was rejected under the second paragraph of 35 U.S.C. §112 as being allegedly indefinite. Claim 19 has been amended as suggested by the Examiner and is no longer indefinite. Hence, it is respectfully requested that this rejection be withdrawn.

Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: February 2, 2006



Jing G. Sun, Ph.D.  
Agent for Applicants  
Registration No. 45,914  
Telephone No. (609) 252-3791  
Facsimile No. (609) 252-4526

**Please forward all future written correspondence relating to this application to:**

Louis J. Wille  
Patent Department  
Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000